Purple Biotech

PPBT

Biotechnology · Healthcare

Price

$1.48

-0.12 (-7.50%)

Market Cap

$204,364

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count falling — buybacks

−97.3% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 88K (2021) → 2K (2025)

Purple Biotech is a small Israeli clinical-stage biotechnology company focused on developing cancer treatments. It does not yet sell any approved products. Its main work involves experimental drugs designed to help the immune system fight tumors, targeting patients with difficult-to-treat solid cancers like colorectal and pancreatic cancer.

The company earns no meaningful revenue today and funds its operations through equity raises and grants, which is typical for clinical-stage biotechs. Purple Biotech operates primarily in Israel with clinical trial activity in the United States and Europe, and its market cap is very small, reflecting the early stage of its pipeline. The central risk is that most experimental cancer drugs fail in clinical trials, and the company will need to raise additional capital to keep its programs running — making dilution and trial outcomes the two biggest factors investors watch.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$4M/ year

↓ Declining (-51% vs prior year)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

5.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~6 months

$6M cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

Purple Biotech has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-23.2%

Weak — -23.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial